SWOG clinical trial number
SWOG-9229

Concurrent Cisplatin, Prolonged Oral Etoposide and Vincristine Plus Chest and Brain Irradiation for Limited Small Cell Lung Carcinoma, Phase II Pilot

Closed
Phase
Accrual
100%
Published
Abbreviated Title
Concurrent Cisplatin, Prolonged Oral Etoposide and Vincristine Plus Chest and Brain Irradiation for Limited Small Cell Lung Carcinoma, Phase II Pilot
Activated
02/15/1993
Closed
05/01/1994

Research committees

Lung Cancer

Publication Information Expand/Collapse

1998

Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: A phase II study of the Southwest Oncology Group (SWOG-9229).

CR Thomas Jr;DJ Giroux;KJ Stelzer;JB Craig;LR Laufman;SA Taylor;JW Goodwin;JJ Crowley;RB Livingtson Int J Radiat Oncol Biol Phys 40(5):1039-1047

1995

Concurrent cisplatin (CDDP), prolonged oral etoposide (E) and vincristine (VCR) plus chest and brain irradiation (RT) induction therapy for limited-stage small cell lung carcinoma (SCLC): Preliminary report of a Southwest Oncology Group study (SWOG-9229)

CR Thomas Jr;DJ Rector;KJ Stelzer;RB Livingston ASCO 14:363(#1111)

Other Clinical Trials

SWOG Clinical Trial Number
S2302

PRAGMATICA - LUNG: A PROSPECTIVE RANDOMIZED STUDY OF RAMUCIRUMAB (LY3009806; NSC 749128) PLUS PEMBROLIZUMAB (MK-3475; NSC 776864) VERSUS STANDARD OF CARE FOR PARTICIPANTS PREVIOUSLY TREATED WITH IMMUNOTHERAPY FOR STAGE IV OR RECURRENT NON-SMALL CELL LUNG CANCER
Research Committee(s)
Lung Cancer
Activated
03/06/2023
Accrual
77%
Open
Phase
SWOG Clinical Trial Number
A082002

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
12/21/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007

RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Research Committee(s)
Lung Cancer
Activated
08/17/2020
Open